NEWS
Stay informed about Quercis developments, partnerships, and media features.
Nominated for 2025 Galien Award
Recognized as a Top 10 Drug Discovery & Development Solutions Provider in Europe (Life Sciences Review, 2023).
CEO Thomas Lines featured in The Silicon Review for leadership in global health innovation.
Upcoming: Phase 3 trial initiation for Kinisoquin™ in cancer-associated thrombosis.
